Inhibikase Therapeutics Replaces Independent Auditor with Deloitte

What Happened
Inhibikase Therapeutics, Inc. announced on August 21, 2026 that its Audit Committee dismissed CohnReznick LLP as the company’s independent registered public accounting firm and immediately appointed Deloitte & Touche LLP as the new independent auditor for the fiscal year ending December 31, 2026. CohnReznick’s audit reports for the years ended December 31, 2025 and 2024 were not adverse, disclaimed, qualified, or modified for uncertainty, audit scope, or accounting principles. CohnReznick had reported a material weakness in internal control over financial reporting during fiscal 2024, which the company disclosed in its 10‑Q for the quarter ended June 30, 2024 and said was remediated by prior management as disclosed in the 10‑Q for the quarter ended September 30, 2024. A letter from CohnReznick to the SEC dated August 26, 2026 is filed as Exhibit 16.1.

Key Details

• Dismissal and appointment effective August 21, 2026; Deloitte appointed for the year ending Dec 31, 2026.
• CohnReznick’s audit reports for 2025 and 2024 were unqualified and contained no disagreements with management.
• CohnReznick had identified a material weakness in 2024 that was disclosed and later remediated (disclosed in 10‑Q filings for 6/30/2024 and 9/30/2024).
• Neither Inhibikase nor anyone acting on its behalf consulted Deloitte about accounting or auditing matters for 2024–2025 or the interim period through the 8‑K filing date.

Why It Matters
A change in independent auditor is a material governance event investors watch because it can affect audit quality, reporting timelines, and confidence in financial controls. The filing shows no current audit disagreements and states the prior material weakness was remediated, which is reassuring, but investors should monitor upcoming quarterly and annual filings (earnings, 10‑Q/10‑K) for Deloitte’s audit opinions and any updates on internal controls. The CohnReznick letter filed as an exhibit provides the outgoing auditor’s response to the disclosure.